At City of Hope, our researchers and clinicians are nationally recognized leaders in developing innovative methods for preventing, detecting and treating urologic cancers.
U. S. News and World Report recently named City of Hope as one of ”America’s Best Hospitals” for cancer. We are the second-highest ranked cancer center in the Los Angeles area to appear on the cancer list and one of only seven centers in California. We also are one of only four in the Los Angeles area to be ranked in urology and one of only seven hospitals in California. City of Hope is home to California's largest prostate cancer program (according to data from the Office of Statewide Health Planning and Development, or OSHPD). As one of a handful of institutes to attain the elite designation of
Comprehensive Cancer Center by the National Cancer Institutes, City of Hope is recognized for its excellence in cancer research and treatment.
The staff of the Division of Urology and Urologic Oncology, headed by
Timothy G. Wilson, M.D. , Pauline and Martin Collins Family Chair in Urology, is recognized for its extensive expertise in minimally invasive surgery. Our surgeons are leaders in robotic-assisted prostatectomy and robotic-assisted laparoscopic cystectomy, both of which offer significant advances in improving patient quality of life.
City of Hope was one of the first cancer centers in the United States to begin performing
robotic-assisted prostatectomy using the da Vinci® surgical system,and our physicians have performed more than any other institution in the Western U.S. and the second in the entire U.S. The most significant benefits to patients are quicker recovery times and decreased blood loss compared to patients undergoing conventional “open incision” procedures.
And, we perform
robotic-assisted cystectomy and bilateral pelvic lymph node dissection for muscle-invasive bladder cancer and have completed the largest number of robotic-assisted radical cystectomy procedures worldwide. In addition, we perform a number of procedures to treat kidney cancer/renal masses, which include radical nephrectomy, nephron-sparing surgery (
open, laparoscopic, or robotic-assisted), cryoablation and radio-frequency ablation (performed percutaneously or laparoscopically).
The Division of Urology also sees many patients who have urologic problems as a result of treatment of non-urologic cancers.
Division research projects are focused on the early diagnosis and prevention of prostate cancer, intraoperative imaging, identification of high-risk prostate cancer patients and quality-of-life issues involving prostate cancer treatment. We are evaluating outcomes and patterns of cancer care for both prostate and bladder cancer and better defining the benefits of robotic-assisted surgery.
